SEC Tracker
Get the app

Terns Pharmaceuticals

Vivo Capital Surplus Fund VIII (Director) plans to sell 8,832 shares, about $66,795

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Apr 1, 2024
  2. Broker: Cowen and Company, LLC
  3. Shares acquired by: IPO Allocation
  4. 10b5-1 plan adopted: Sep 29, 2023

All of Vivo Capital Surplus Fund VIII's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 5,451 shares at $6.99 on Apr 1, 2024 · Form 4
  • Sold 3,050 shares at $6.65 on Apr 2, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Terns Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Prothena PRTA public float $327M, Jun 30, 2025
  2. Altimmune ALT public float $327M, Jun 30, 2025
  3. Aura Biosciences AURA public float $321M, Jun 30, 2025
  4. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  5. Nektar Therapeutics NKTR public float $318M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.